BTLS 📈 Biotalys - Overview
Exchange: BR • Country: Belgium • Currency: EUR • Type: Common Stock • ISIN: BE0974386188
BTLS: Biofungicides, Bioinsecticides
Biotalys NV, an agricultural technology company, discovers and develops novel biological products in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6 targeting botrytis, powdery mildew, and anthracnose in fruits and vegetables; BIOFUN-7 targeting leafspot disease in cowpeas and other legumes; and BIOFUN-4 targeting oomycetes in fruits and vegetables. The company was formerly known as Agrosavfe NV. Biotalys NV was incorporated in 2013 and is headquartered in Gent, Belgium. Web URL: https://www.biotalys.com
Additional Sources for BTLS Stock
BTLS Stock Overview
| Market Cap in USD | 117m |
| Sector | Basic Materials |
| Industry | Agricultural Inputs |
| GiC Sub-Industry | Fertilizers & Agricultural Chemicals |
| IPO / Inception |
BTLS Stock Ratings
| Growth 5y | -83.1% |
| Fundamental | -28.4% |
| Dividend | - |
| Rel. Strength Industry | -16860 |
| Analysts | - |
| Fair Price Momentum | 2.51 EUR |
| Fair Price DCF | - |
BTLS Dividends
No Dividends PaidBTLS Growth Ratios
| Growth Correlation 3m | -55.4% |
| Growth Correlation 12m | -44.4% |
| Growth Correlation 5y | -91.4% |
| CAGR 5y | -20.25% |
| CAGR/Mean DD 5y | -0.70 |
| Sharpe Ratio 12m | -0.79 |
| Alpha | -44.38 |
| Beta | 0.33 |
| Volatility | 39.65% |
| Current Volume | 18.4k |
| Average Volume 20d | 20.8k |
What is the price of BTLS stocks?
As of December 21, 2024, the stock is trading at EUR 3.13 with a total of 18,403 shares traded.
Over the past week, the price has changed by -2.49%, over one month by +7.56%, over three months by +0.97% and over the past year by -25.30%.
As of December 21, 2024, the stock is trading at EUR 3.13 with a total of 18,403 shares traded.
Over the past week, the price has changed by -2.49%, over one month by +7.56%, over three months by +0.97% and over the past year by -25.30%.
Is Biotalys a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Biotalys (BR:BTLS) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.36 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BTLS as of December 2024 is 2.51. This means that BTLS is currently overvalued and has a potential downside of -19.81%.
Probably not. Based on ValueRay Fundamental Analyses, Biotalys (BR:BTLS) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -28.36 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BTLS as of December 2024 is 2.51. This means that BTLS is currently overvalued and has a potential downside of -19.81%.
Is BTLS a buy, sell or hold?
Biotalys has no consensus analysts rating.
Biotalys has no consensus analysts rating.
What are the forecast for BTLS stock price target?
According to ValueRays Forecast Model, BTLS Biotalys will be worth about 2.7 in December 2025. The stock is currently trading at 3.13. This means that the stock has a potential downside of -12.78%.
According to ValueRays Forecast Model, BTLS Biotalys will be worth about 2.7 in December 2025. The stock is currently trading at 3.13. This means that the stock has a potential downside of -12.78%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 5.2 | 66.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 2.7 | -12.8% |